Related Experiment Video
Updated: May 22, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
A novel strategy for sorafenib-resistant hepatocellular carcinoma: autotaxin Inhibition by PF-8380
Bong Jun Kwak1, Jung Hyun Park2,3, Ok-Hee Kim3,4
1Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Abstract:
By inhibiting the conversion of lysophosphatidylcholine into lysophosphatidic acid, a process pivotal to tumor progression, the autotaxin (ATX) inhibitor PF-8380 offers a new anticancer therapeutic strategy, distinct from the action mechanism of sorafenib. This study explored the potential anticancer effects of the PF-8380 on hepatocellular carcinoma (HCC) cells, especially sorafenib-resistant strains. The investigation included both in vitro and in vivo experiments to evaluate the impact of PF-8380 treatment on epithelial-mesenchymal transition (EMT) and autophagy markers. An orthotopic HCC model served as the in vivo platform. PF-8380 showed a significant reduction in cell viability in both sorafenib-susceptible and resistant HCC cells. It effectively altered EMT by increasing E-cadherin and reducing Snail levels, and inhibited autophagy, as indicated by changes in LC3 and p62 markers. These effects were consistently observed in the orthotopic HCC mouse model, reinforcing PF-8380's potential as a dual inhibitor of EMT and autophagy in HCC treatment. Our research indicates that PF-8380 could provide substantial therapeutic benefits in the treatment of HCC, even in cases resistant to sorafenib, primarily by suppressing both EMT and autophagy processes.
Insights
The autotaxin inhibitor PF-8380 effectively combats hepatocellular carcinoma (HCC) by reducing cell viability and suppressing both epithelial-mesenchymal transition (EMT) and autophagy, even in sorafenib-resistant cases.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality.
- Sorafenib is a standard treatment, but resistance frequently develops.
- Autotaxin (ATX) is a key enzyme in lysophosphatidic acid production, promoting tumor progression.
Purpose of the Study:
- To investigate the anticancer potential of the ATX inhibitor PF-8380 against HCC cells.
- To evaluate PF-8380's efficacy in sorafenib-resistant HCC models.
- To assess PF-8380's impact on epithelial-mesenchymal transition (EMT) and autophagy.
Main Methods:
- In vitro studies on HCC cell lines (sorafenib-susceptible and resistant).
- In vivo experiments using an orthotopic HCC mouse model.
- Analysis of EMT markers (E-cadherin, Snail) and autophagy markers (LC3, p62).
Main Results:
- PF-8380 significantly reduced HCC cell viability.
- PF-8380 treatment suppressed EMT by increasing E-cadherin and decreasing Snail.
- PF-8380 inhibited autophagy, evidenced by altered LC3 and p62 levels.
- These effects were confirmed in the in vivo HCC model.
Conclusions:
- PF-8380 demonstrates potent anticancer activity in HCC, including sorafenib-resistant types.
- PF-8380 acts as a dual inhibitor of EMT and autophagy.
- PF-8380 represents a promising therapeutic strategy for HCC treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...